- “In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.”
- Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy.
- RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable.
The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q). Companies such as Calidi Biotherapeutics (NYSE American: CLDI) are working hard to discover more effective treatments to curb the rising numbers. Calidi recently presented key data at two prominent scientific conferences regarding its new generation of targeted antitumor virotherapies and viral vectors (https://ibn.fm/9johm).
“Over the last 30 years, the risk of dying from cancer has steadily declined, sparing some four million lives in the United States,” the ACA reported. “This downward trend can partially be explained by big wins in smoking cessation, early cancer detection and treatment advancements. Cancer incidence, however, is…
NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
